drugset
drugset / Trial / NCT04154670

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

NCT04154670 ↗

Phase 1 Completed 23 enrolled Ensoma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is being conducted in healthy subjects and in subjects with a mild or moderate decrease in GFR (subjects with renal impairment).

Timeline

Start
2019-11-07
Primary completion
2020-03-24
Completion
2020-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject MGTA-145 Protein / enzyme biologic — Intravenous

Indications

impaired renal function disease